Boston, MA -- (ReleaseWire) -- 06/13/2014 -- South Korean pharmaceutical firms will see revenue growth predominantly through exports. The domestic pharmaceutical market will come under further pressure from the government, which is seeking to limit pharmaceutical spending to prevent costs from escalating. However, as the timeline for implementing these policies is currently unknown, there is some short-term stability for the pharmaceutical market.
Headline Expenditure Projections
- Pharmaceuticals: KRW16,106.7bn (USD14.71bn) in 2013 to KRW16,558.5bn (USD14.78bn) in 2014; +2.8% in local currency terms and +0.5% in US dollar terms. Forecast broadly in line with Q214. Growth in US dollar terms affected by currency fluctuations.
- Healthcare: KRW103,030.3bn (USD94.12bn) in 2013 to KRW110,790.5bn (USD98.92bn) in 2014; +7.5% in local currency terms and +5.1% in US dollar terms. Forecast broadly in line with Q214. Growth in US dollar terms affected by currency fluctuations.
View Full Report Details and Table of Contents
In Q3 2014, South Korea ranks second out of the 19 countries surveyed in the Asia Pacific region. South Korea's score for its Rewards variable is second only to Japan, indicating the country's favourable longerterm standing in terms of its pharmaceutical market development. However, we note that Risks - particularly in relation to pharmaceutical pricing and reimbursement - will remain present, especially as the population ages and requires more public sector resources.
Key Trends & Developments
- In April 2014, BioAlliance Pharma entered an exclusive supply and licence agreement for Sitavig (acyclovir Lauriad) with Daewoong Pharmaceutical for commercialisation rights in South Korea. Under this agreement, Daewoong will be in charge of registering Sitavig in South Korea, and BioAlliance is eligible to receive significant up-front and milestone payments. The agreement also includes a doubledigit royalty rate.
- In March 2014, South Korea's Ministry of Health and Welfare and the Mexican health ministry signed a memorandum of understanding (MoU) in the field of pharmaceuticals, medical devices and cosmetics. The MoU was signed on behalf of the health ministries of the two countries by Mexico's Federal Commission for the Protection against Sanitary Risk (COFEPRIS) and South Korea's Ministry of Drug and Food Safety (MDFS). The MoU aims to strengthen technical cooperation between the two countries, which in turn will help patients. The health authorities also agreed to promote innovation and cooperation in the pharmaceutical sector, with the aim of improving both countries' economies.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - South Korea
- Singapore Pharmaceuticals & Healthcare Report Q3 2014
- Hong Kong Pharmaceuticals & Healthcare Report Q3 2014
- Germany Pharmaceuticals & Healthcare Report Q3 2014
- Japan Pharmaceuticals & Healthcare Report Q3 2014
- Australia Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014